Company intelligence / Profile preview

Novosom

Halle (Saale), Germany

Ownership: Private
Development stage: Other

Overview

Developed liposome-based Smarticles technology for nucleic acid delivery; licensed CD40-targeted antisense inhibitors; no reported clinical trials or results

Therapeutic areas: HematologyImmunologyGastroenterology
Modalities: Lipid nanoparticle delivery therapyAntisense oligonucleotide
Industry: Biotech

Partnerships

Isis Pharmaceuticals (licensor)

Beyond the preview

Go deeper on Novosom.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novosom.

Explore the full profile